FIG 8.

(A to D) The pharmacodynamics of meropenem (A and B) and tobramycin (C and D) in the rabbit model of pseudomonal meningoencephalitis. For meropenem, the pharmacodynamics are quantified using systemic drug exposure (i.e., fT > MIC in plasma; panel A) and drug exposure within the CSF (i.e., AUC:MIC; panel B). For tobramycin, systemic and effect site drug exposures are shown in panels C and D, respectively. Meropenem exhibits significant bactericidal activity in CSF. In contrast, the antibacterial effect of tobramycin is minimal.